847416-31-3

Basic information

• Product Name: Carbamic acid, [cis-4-[(4-nitrobenzoyl)oxy]cyclohexyl]-, 1,1-dimethylethyl ester
• CAS NO: 847416-31-3
• Molecular Formula: C18H24N2O6
• Molecular Weight: 364.398
• Mol File: 847416-31-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [cis-4-[(4-nitrobenzoyl)oxy]cyclohexyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [cis-4-[(4-nitrobenzoyl)oxy]cyclohexyl]-, 1,1-dimethylethyl ester(847416-31-3)
• EPA Substance Registry System: Carbamic acid, [cis-4-[(4-nitrobenzoyl)oxy]cyclohexyl]-, 1,1-dimethylethyl ester(847416-31-3)

Safety Data

• Hazardous Substances Data: 847416-31-3(Hazardous Substances Data)

Upstream product

• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 62-23-7 4-nitro-benzoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1007306-61-7 (1S,4S)-4-((tert-butoxycarbonyl)amino)-cyclohexyl methanesulfonate 
• 167081-25-6 cis-(4-hydroxycyclohexyl)carbamic acid tert-butyl ester 

Relevant articles and documents

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.